Business Wire

SABIO-GROUP

15.3.2021 10:02:05 CET | Business Wire | Press release

Share
Sabio Group Acquires Voicebot Specialist Fonetic

Sabio Group , Europe’s leading technology and digital CX service provider, has acquired Fonetic , a leading Spanish provider of cloud-enabled AI voicebots, chatbots and customer behaviour analytics solutions. The announcement strengthens Sabio’s AI and Automation solutions offering, enabling the company’s goal of supporting customers with its own truly innovative range of CX solutions to complement its broad multi-vendor product portfolio.

Since its formation in 2006, Fonetic has established itself as a specialist in the provision of voice recognition, Natural Language Processing (NLP) and Artificial Intelligence-powered voicebot and chatbot solutions. Fonetic solutions help organisations to digitally transform their CX operations. The company currently manages, processes and monitors over 200 million interactions per year for major clients including Generali, Axa, Banco Santander, Endesa, , Linea Directa, Mapfre, Multiasistencia and Vodafone.

“We’re now at the stage where it’s reasonable to expect that almost every customer interaction will soon be fronted by AI in some shape or form, and that AI-enabled capabilities are poised to transform customer experience,” explained Sabio’s CEO Jonathan Gale. “With its proven voicebot, chatbot, customer behaviour analytics and visualisation capabilities, Fonetic directly addresses this challenge. The company not only brings an incredibly talented team but valuable expertise in CX digital transactions that will be an important addition to Sabio’s own IP portfolio.”

“At Fonetic we can demonstrate how our voicebots and chatbots perform at scale. This helps our clients to digitally transform their customer engagement by increasing CX efficiencies while also securing significant increases in customer satisfaction,” added Juan Manuel Soto, Fonetic’s CEO and Founder. “As part of the Sabio Group we can bring our voicebot and chatbot offering to a much broader market, especially as AI and automation adoption within the CX sector is set to accelerate exponentially.”

Fonetic works closely with Generali Spain’s Digital Transformation team, and designed and developed the multichannel Bot for Generali in Spain. Commenting, Generali Spain’s Head of Business Transformation and Control, Enrique Lorente said: “Fonetic’s Bot expertise and design skills are a key factor behind the success of our cognitive Bot - by providing a conversational assistant to our distributors and customers, offering automatic claim management, one of Generali’s key and highly volume processes, and allowing them to use the channel of their choice, in an easy and natural way. We look forward to being part of their continued success.”

Fonetic voicebots and chatbots are bot-agnostic and can be deployed using either the company’s own technology or integrated with third-party NLP assets to get the most out of tools such as Microsoft Bot Framework & Luis, Google Dialogflow, IBM Watson, Nuance’s Nina, Sabio’s own solution flexAnswer, Genesys or home assistants like Alexa and Google Home.

www.fonetic.com

www.sabiogroup.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye